The ₹1 Crore Barrier

Bundling the model to the hardware is a commercial decision, not a technical necessity, and it is a durable one. It converts a reproducible piece of software into a physical unit that can be priced, shipped and defended. It makes the vendor the only source of images the model will accept. And it converts what would otherwise be an operating cost into a capital purchase — the single hardest line for an independent clinic to approve.

It also fixes who the customer can be. A price set against Western reimbursement and Western cycle volumes selects for large, corporate chains anywhere it is exported. In India that leaves roughly 90% of clinics outside the market — not because they are small in patients, but because their capital base was never the one the price was written for.

The clinics priced out are not marginal. They are the standalone and regional units that carry the majority of cycles in the country, run by embryologists with the same training and the same caseload as anyone in the tier above them. What separates them is a balance sheet, and the separation compounds in three directions at once.

Their labs stay fully manual, so the variance and the fatigue on the other two pages in this register go unaddressed — and those are the labs where the volume is. Their cycles produce no structured data, so the domestic evidence base that ought to be growing fastest does not grow at all. And the gap between a chain lab and an independent one widens every year the technology is available but unaffordable.

Meanwhile the equipment those clinics do own is not the limitation. The microscope on the bench already resolves everything the model needs to read. The image is there; only the licence to read it with software is missing.

Unbundling. Forlivf is a pure software layer that runs on the microscope camera and workstation the lab already has. There is no incubator to buy, no chamber to install, and no capital equipment required — which removes the barrier at its source rather than discounting it.

The commercial shape follows the same logic. Setup is ₹0: the licence, onboarding, EMR integration and staff training are included, with no contract minimum, so a clinic can start without a capital approval at all. The only ongoing cost is a flat per-cycle fee, and that fee sits as a line item on the patient’s out-of-pocket treatment bill — collected and remitted by the clinic, taking nothing out of the hospital’s own margin. A month with no cycles is billed nothing.

The point of pricing it this way is not that it is cheaper. It is that it is reachable by the nine clinics in ten the current model excludes — which is the only version of this technology that changes national outcomes rather than the outcomes of the labs that were already leading.